{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"190"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"This outcome measure summarized the overall occurrence of adverse events related to nilotinib during the study. A study drug-related adverse event was defined as any adverse event assessed by the investigator as related to nilotinib and reported during the nilotinib treatment consolidation (NTCS) phase, the treatment-free remission (TFR) phase, or the nilotinib treatment re-initiation (NTRI) phase.","groups":[{"description":"Participants who had received at least 2 years of first-line nilotinib treatment and achieved a deep molecular response (MR4.5) entered the nilotinib treatment consolidation (NTCS) phase. During this phase, participants received nilotinib 300 mg twice daily for 52 weeks.","id":"OG000","title":"NTCS Phase"},{"description":"Participants who completed the nilotinib treatment consolidation (NTCS) phase and maintained major molecular response entered the treatment-free remission (TFR) phase. During the TFR phase, nilotinib treatment was discontinued and participants were monitored regularly for molecular response.","id":"OG001","title":"TFR Phase"},{"description":"Participants who experienced loss of major molecular response during the treatment-free remission (TFR) phase entered the nilotinib treatment re-initiation (NTRI) phase. During this phase, nilotinib treatment was re-initiated at a dose of 300 mg twice daily.","id":"OG002","title":"NTRI Phase"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety population included all participants who received at least one dose of nilotinib during any study phase (NTCS or NTRI).","reportingStatus":"POSTED","timeFrame":"From first dose of nilotinib through up to approximately 11 years of study participation, including the NTCS, TFR, and NTRI phases","title":"Percentage of Participants With Treatment-emergent Adverse Events During the Entire Study","type":"SECONDARY","unitOfMeasure":"Participants"}